Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes that has shown neuroprotective potential in Parkinson's disease. Several clinical trials have investigated its disease-modifying effects.
¶ GLP-1 and Neurodegeneration
GLP-1 receptors are expressed in the brain, particularly in:
Activation of GLP-1 receptors leads to:
- Increased insulin signaling
- Reduced neuroinflammation
- Enhanced mitochondrial function
- Protection against oxidative stress
- Promotion of autophagy
The concept of using GLP-1 agonists for PD stems from:
- Type 3 Diabetes Hypothesis - links insulin resistance to neurodegeneration
- Preclinical evidence - neuroprotection in animal models
- Established safety profile - already approved for diabetes
Study: Athauda et al., The Lancet (2017)
| Parameter |
Results |
| Design |
Randomized, double-blind, placebo-controlled |
| Patients |
62 with moderate PD |
| Dose |
Exenatide 2mg weekly (Bydureon) |
| Duration |
48 weeks treatment, 12 weeks washout |
| Primary Outcome |
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor score |
Results:
- Exenatide group showed significant improvement in MDS-UPDRS motor scores vs placebo
- Benefits persisted after washout period
- Well-tolerated with minimal side effects
Study: Foltynie et al., EBioMedicine (2023)
Results:
- Confirmed motor and non-motor symptom benefits
- Imaging showed reduced dopaminergic neuron loss
- Cognitive benefits observed in some patients
| Trial |
Phase |
Status |
Notes |
| EXENATIDE-PD |
Phase III |
Recruiting |
Larger confirmatory trial |
| Exenatide-Young |
Phase II |
Recruiting |
Early PD patients |
Exenatide (GLP-1 agonist)
|
v
GLP-1 Receptor Activation
|
+---> PI3K/Akt Pathway ----> Enhanced neuronal survival
|
+---> AMPK Activation ----> Improved metabolism
|
+---> NF-kB Inhibition ----> Reduced neuroinflammation
|
+---> mTOR Modulation ----> Enhanced autophagy
|
+---> Mitochondrial Protection ----> Reduced oxidative stress
-
Dopaminergic neuron protection
- Reduces apoptosis in substantia nigra
- Promotes neurite outgrowth
- Enhances dopamine release
-
Neuroinflammation reduction
- Decreases microglial activation
- Reduces pro-inflammatory cytokines
- Modulates T-cell response
-
Metabolic effects
- Improves insulin sensitivity
- Enhances glucose metabolism
- Reduces endoplasmic reticulum stress
| Drug |
Route |
Half-life |
PD Trials |
Status |
| Exenatide |
SubQ weekly |
2.4 days |
Phase III |
Most data |
| Liraglutide |
SubQ daily |
13 hours |
Phase II |
Positive signals |
| Semaglutide |
SubQ weekly |
7 days |
Phase II |
Planned |
| Duraglutide |
SubQ weekly |
5-7 days |
Preclinical |
- |
- Nausea (most common, usually transient)
- Vomiting
- Diarrhea
- Decreased appetite
- Injection site reactions
- Pancreatitis - rare but noted warning
- Thyroid C-cell tumors - boxed warning for rodents
- Hypoglycemia - risk when combined with insulin/secretagogues
- Kidney function - dose adjustment in renal impairment
- Established long-term safety in diabetes
- Once-weekly formulation (Bydureon)
- Good brain penetration
- Good tolerability
- Not yet approved for PD indication
- Available off-label for PD (diabetes drug repurposing)
- Recommended by some Movement Disorder Specialists
-
Consider for PD patients with:
- Type 2 diabetes comorbidities
- Rapid disease progression
- Cognitive complaints
-
Dosing approach:
- Start low (5 mcg twice daily)
- Escalate to 10 mcg twice daily
- Consider weekly formulation for convenience
- Generic exenatide available
- Insurance coverage varies
- May be cost-effective compared to emerging therapies
- GLP-1 + GBA modulation - synergistic neuroprotection
- GLP-1 + physical exercise - additive benefits
- GLP-1 + existing PD meds - no known interactions
- CSF neurofilament light chain (NfL) as response marker
- Metabolic imaging (FDG-PET) for treatment effects
- Clinical scales remain primary endpoint
¶ Questions Remaining
- Optimal patient selection criteria
- Long-term disease modification effects
- Mechanism of action in humans
- Comparison to other neuroprotective strategies
- Exenatide and the treatment of Parkinson's disease - Athauda et al., Lancet 2017
- GLP-1 receptor agonists for Parkinson's disease - Review of clinical evidence
- Neuroprotective mechanisms of GLP-1 agonists - Preclinical mechanisms
See also: GLP-1 Receptor Agonists, Parkinson's Disease